Post-Exposure Prophylaxis Among Healthcare Workers
- Rationale
Post-exposure prophylaxis (PEP) is an important component of occupational infection prevention and control for healthcare personnel (HCP). It comprises the prompt assessment and management of healthcare personnel following a potential occupational exposure to an infectious pathogen, with the objective of preventing infection, reducing the risk of transmission, and minimizing subsequent morbidity and public health consequences.
Healthcare personnel may be exposed to infectious agents through percutaneous injuries, mucous membrane exposures, contact with non-intact skin, respiratory exposures, or other contact with infectious patients, specimens, tissues, or body fluids. The need for PEP depends on the infectious agent, the nature and severity of the exposure, the infectious status of the source, the susceptibility or immune status of the exposed HCP, and the availability and effectiveness of an appropriate preventive intervention.
A comprehensive occupational exposure management program therefore requires rapid recognition and reporting of exposures, immediate first aid, exposure risk assessment, evaluation and testing of the source patient when appropriate, assessment of the exposed HCP, timely administration of PEP when indicated, follow-up testing and clinical monitoring, documentation, counselling, and measures to prevent secondary transmission and future occupational exposures.
Clearly defining whether an occupational exposure has occurred may require detailed assessment of the circumstances surrounding the incident, including the type of contact, body fluid involved, route of exposure, duration and severity of exposure, use of PPE, and adherence to Standard and Transmission-Based Precautions. When recommended infection prevention practices are correctly implemented, the risk of exposure may be substantially reduced. However, appropriate monitoring may still be required following exposure to highly transmissible pathogens because an unrecognized exposure or subsequent development of infection may have implications for both the affected HCP and patients.
➡️Bloodborne Pathogens
Bloodborne pathogens of particular occupational concern include HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV). Healthcare personnel may be exposed through needlestick injuries, other sharps injuries, or contact of blood or other potentially infectious materials (OPIM) with mucous membranes or non-intact skin.
The management of bloodborne pathogen exposures differs according to the pathogen. Effective PEP is available for HIV and HBV in appropriate circumstances, whereas no recommended PEP regimen is currently available for HCV. For HCV, the appropriate strategy is prompt baseline and follow-up testing to identify infection early and facilitate treatment if infection develops. CDC recommends testing HCP after potential HCV exposure rather than administering prophylactic antiviral treatment.
1. Human Immunodeficiency Virus
HIV establishes infection rapidly following exposure; therefore, occupational HIV exposure should be treated as a medical urgency. When PEP is indicated, antiretroviral therapy should be initiated as soon as possible, because earlier initiation provides a greater opportunity to prevent establishment of infection. Current CDC guidance continues to emphasize initiation within 72 hours of exposure, with the first dose administered without unnecessary delay while relevant source or laboratory information is being obtained.
The decision to administer HIV PEP should be based on an assessment of the exposure route, the type and amount of potentially infectious fluid, the presence of non-intact skin or mucous membrane exposure, and the HIV status or likelihood of HIV infection in the source patient. PEP is not recommended when there is no substantial risk of HIV transmission.
The recommended course of HIV PEP is 28 days. The exposed HCP should receive appropriate baseline assessment, counselling, monitoring for adverse effects, and follow-up HIV testing according to the applicable occupational HIV PEP protocol.
The biological rationale for HIV PEP is that antiretroviral drugs can inhibit early viral replication and thereby reduce the probability that exposure will progress to established infection. Evidence from experimental models and accumulated occupational experience supports the importance of initiating PEP as early as possible.
A discarded needle found in the community represents a different exposure scenario from a known occupational exposure to blood from an HIV-infected source. Routine HIV PEP is not recommended for discarded-needle exposures when the circumstances do not constitute a substantial-risk exposure; management should instead be based on an individualized risk assessment.
2. Hepatitis B Virus
HBV is highly infectious and can be transmitted through occupational exposure to infected blood and certain body fluids. Unlike HCV, effective preventive interventions are available, including HepB vaccination and hepatitis B immune globulin (HBIG). Therefore, the vaccination and serological status of the exposed HCP are central to post-exposure management. CDC recommends hepatitis B vaccination for HCP with reasonably anticipated occupational exposure and recommends documenting vaccine response when indicated.
The need for HBV PEP is determined by the combination of:
· the HCP's documented HepB vaccination status;
· previous anti-HBs results, when available;
· the HBsAg status of the source patient; and
· whether the HCP has demonstrated an adequate vaccine response.
HCP with documented completion of the HepB vaccine series and a documented anti-HBs level ≥10 mIU/mL are considered protected and require no HBV PEP following exposure, regardless of the source patient's HBsAg status.
HCP with anti-HBs of 10 mIU/mL or more after receiving the primary vaccine series are considered immune. People who are immunocompetent have long-term protection and should not need further anti-HBs testing. Clinicians with anti-HBs of less than 10 mIU/mL after receiving the primary series should be revaccinated.
An increasing number of clinicians have received routine HepB vaccination during childhood. Postvaccination serological testing is not recommended after routine infant or adolescent HepB vaccination. Because vaccine-induced anti-HBs wanes over time, testing clinicians for anti-HBs years after vaccination might not distinguish vaccine non-responders from responders.
Preexposure assessment of current or past anti-HBs results upon hire or matriculation, followed by one or more additional doses of HepB vaccine for clinicians with anti-HBs of less than 10 mIU/mL and retesting anti-HBs, if necessary, helps to ensure that clinicians will be protected if they have an exposure to HBV-containing blood or body fluids.
For vaccinated HCP without previous post-vaccination serological documentation, the HCP's anti-HBs level and the source patient's HBsAg status should be assessed promptly within the first 24 hrs after exposure. When anti-HBs is <10 mIU/mL and the source is HBsAg-positive or has an unknown HBsAg status, HBIG and revaccination are indicated. When the source is HBsAg-negative, revaccination without HBIG is appropriate.
For unvaccinated or incompletely vaccinated HCP exposed to an HBsAg-positive or unknown-status source, HBIG and HepB vaccine should be administered as soon as possible, followed by completion of the vaccine series. HBIG and HepB vaccine may be administered simultaneously but at different anatomical sites (two deltoid) HCP who have completed two complete HepB vaccine series but remain anti-HBs <10 mIU/mL are considered vaccine non-responders. If exposed to an HBsAg-positive or unknown-status source, they should receive two doses of HBIG one month apart; additional HepB vaccination is not recommended in this situation. According to body weight. And under medical supervision. Because anti-HBs obtained before completion of a documented vaccine series cannot reliably establish vaccine-mediated protection, HCP who cannot provide documentation of the required vaccine doses should be managed as unvaccinated or incompletely vaccinated and should complete the vaccine series. Post-vaccination anti-HBs testing should be performed, generally 1–2 months after completion of the vaccine series, with consideration of the effect of HBIG on interpretation of anti-HBs testing.
Following exposure to an HBsAg-positive or unknown-status source, HCP who are susceptible or have anti-HBs <10 mIU/mL should also undergo appropriate baseline and follow-up testing for HBV infection. CDC recommends baseline total anti-HBc testing and follow-up HBsAg and total anti-HBc testing approximately six months after exposure.
Vaccinated HCP, who are non-responders, should be tested for HBsAg and anti-HBc to determine infection status. Those HCPs should be considered susceptible to HBV
infection if hepatitis markers are negative.
3. Hepatitis C Virus
There is currently no recommended post-exposure prophylaxis for HCV. Consequently, management focuses on early identification of infection through baseline and follow-up testing. Early detection is important because effective curative antiviral treatment is available for established HCV infection.
The risk of HCV transmission following occupational exposure is primarily associated with percutaneous exposure to infected blood. Appropriate management therefore includes prompt reporting and assessment of the exposure, testing of the source patient when appropriate, baseline testing of the exposed HCP, and follow-up testing according to the applicable HCV occupational exposure protocol.
Vaccine-Preventable and Other Occupational Infections
For vaccine-preventable infections, the primary occupational prevention strategy is to ensure that HCP have appropriate vaccination and documented evidence of immunity where applicable. Following an exposure, management depends on the HCP's immune status, the characteristics of the exposure, the infectiousness of the source, and whether an effective PEP intervention exists.
➡️Mumps
Mumps can be transmitted through respiratory and oral secretions. Healthcare-associated transmission is uncommon but may occur, particularly because some infected individuals have mild or asymptomatic disease.
Prevention relies on ensuring that HCP have presumptive evidence of immunity and on appropriate infection prevention measures. There is no routinely recommended PEP following mumps exposure. During outbreaks, public health authorities may recommend additional vaccination for certain HCP groups.
Asymptomatic HCP with presumptive evidence of immunity generally do not require work restriction following exposure but should undergo appropriate symptom monitoring during the relevant incubation period.
➡️Measles
Measles is highly contagious and can be transmitted through the airborne route. Healthcare settings are particularly important environments for transmission because patients with measles may present before the diagnosis is recognized and may expose multiple HCP and patients.
Prevention therefore depends on ensuring that HCP have presumptive evidence of immunity, rapid recognition and isolation of suspected cases, appropriate Airborne Precautions, and prompt assessment of exposed HCP.
For HCP without presumptive evidence of immunity, post-exposure vaccination should be administered as soon as possible when indicated. The purpose of post-exposure vaccination is to provide protection against measles following exposure; however, vaccination does not replace appropriate monitoring and work-restriction measures when these are indicated. HCP with documented presumptive evidence of immunity generally do not require PEP or work restriction following exposure.
➡️Rubella
Rubella is generally a mild illness in adults but is of particular public health concern because infection during pregnancy can cause severe congenital abnormalities.
Prevention in healthcare settings therefore depends on ensuring that HCP have presumptive evidence of immunity, applying appropriate infection-control precautions, and excluding infectious HCP from work when indicated.
Unlike measles, post-exposure vaccination has not been demonstrated to prevent rubella infection after exposure. Therefore, rubella vaccine is not considered effective PEP. Susceptible exposed HCP should be managed through appropriate monitoring and work restrictions according to public health guidance. Vaccination may nevertheless be indicated to establish immunity for future exposures.
➡️Varicella-Zoster Virus (VZV)
VZV is highly transmissible in healthcare settings and may spread through direct contact and through airborne or aerosolized particles associated with vesicular lesions and respiratory secretions. Healthcare-associated transmission may occur from patients, visitors, or infected HCP.
The primary prevention strategy is to ensure that HCP have documented evidence of immunity to varicella and to apply appropriate infection prevention and control measures.
For exposed HCP without evidence of immunity, post-exposure vaccination should be administered as soon as possible. Vaccination within 3–5 days after exposure may prevent or modify disease; vaccination administered later than five days may still provide protection against subsequent exposures and should not be omitted solely because the optimal post-exposure window has passed.
For HCP who lack evidence of immunity and have a contraindication to varicella vaccination, varicella-zoster immune globulin (VariZIG) should be considered when they are at increased risk of severe varicella, including pregnant or immunocompromised HCP. It should be administered as soon as possible after exposure, within the recommended post-exposure window. Administration of VariZIG may prolong the incubation period, requiring an appropriately extended period of monitoring.
Asymptomatic HCP without evidence of immunity who have been exposed should be monitored for signs and symptoms of varicella and managed according to applicable work-restriction recommendations. HCP who develop varicella should be excluded from work until they are no longer infectious, including until lesions have dried and crusted or, in the case of non-vesicular lesions, until no new lesions have appeared for the required period.
➡️Diphtheria
Healthcare-associated transmission of diphtheria is uncommon but may occur following close, unprotected contact with respiratory or oral secretions or drainage from infected cutaneous lesions. Higher-risk occupational activities may include airway procedures, close physical examination, and direct handling of infected lesions or their secretions without appropriate PPE.
The rationale for PEP is to prevent development of disease and interrupt further transmission among exposed HCP. Management may include assessment of vaccination status, administration of an appropriate diphtheria-containing vaccine when indicated, antimicrobial prophylaxis, microbiological assessment, and temporary exclusion from work when clinically or epidemiologically indicated.
HCP with significant exposure should therefore be evaluated promptly according to public health and infection-control guidance.
➡️Pertussis
Healthcare-associated transmission of Bordetella pertussis can occur between patients and HCP. Vaccination reduces the risk of disease but does not completely eliminate the possibility of infection because immunity may wane over time and vaccine effectiveness is not absolute.
Following a significant exposure, HCP should therefore undergo individual risk assessment regardless of vaccination status. When indicated, antimicrobial PEP should be provided, particularly to HCP who are likely to have contact with individuals at increased risk of severe pertussis.
The preferred antimicrobial agents for PEP include azithromycin, clarithromycin, or erythromycin, according to the applicable clinical guidance. HCP who develop suspected or confirmed pertussis should be managed to prevent transmission to patients and other staff, including appropriate exclusion from work during the infectious period.
➡️Tetanus
Tetanus immunoglobulin (TIG) provides immediate passive protection by neutralizing circulating tetanus toxin, but it does not induce long-term immunity. Therefore, TIG is indicated for individuals with tetanus-prone wounds who are not adequately vaccinated or whose vaccination status is unknown, because they may lack sufficient protective antitoxin antibodies. TIG is also recommended for immunocompromised individuals, even when fully vaccinated, because their immune response to previous vaccination may be inadequate to provide reliable protection. When both TIG and tetanus-containing vaccine are indicated, they should be administered at separate anatomical sites using separate syringes.
➡️Meningococcal Disease
Healthcare-associated transmission of Neisseria meningitidis is uncommon but may occur following direct exposure to respiratory secretions, particularly during airway management or other procedures that generate contact with oral or respiratory secretions.
Prevention includes Standard Precautions, Droplet Precautions for patients with suspected or confirmed meningococcal disease, rapid diagnosis and treatment, and appropriate chemoprophylaxis for HCP who have had a significant exposure.
Chemoprophylaxis is intended to eradicate nasopharyngeal carriage and prevent subsequent invasive disease. It should be administered as soon as possible after a significant exposure, with commonly recommended options including rifampin, ciprofloxacin, or ceftriaxone according to applicable antimicrobial-resistance considerations and public health guidance.
HCP who develop suspected or confirmed invasive meningococcal disease should be excluded from work until they have received appropriate antimicrobial therapy for at least 24 hours.
➡️Rabies
Rabies is a nearly universally fatal disease once clinical symptoms develop; consequently, prevention following a genuine exposure is critical. Occupational transmission to HCP during routine patient care has not been confirmed, and routine healthcare contact with a patient with rabies is not itself an indication for PEP.
PEP is considered when an HCP has had a potential exposure capable of transmitting rabies, such as a bite, scratch, or mucous membrane exposure to infectious material. Immediate and thorough wound cleansing is an essential first step because it reduces the amount of virus at the exposure site.
The decision to administer PEP should be based on the type of exposure, the animal/source characteristics, the circumstances of the exposure, and applicable public health guidance.
According to Egyptian Ministry of Health and Population recommendations (2025), for previously unvaccinated individuals, rabies PEP consists of rabies immunoglobulin (RIG) on Day 0 and rabies vaccine on Days 0, 3, 7, and 14. For previously vaccinated individuals, two vaccine doses are administered on Days 0 and 3, and RIG is not indicated.